In our study, except for four cases, all LNUC were PD-L1-negative with very low TPS and IC percentages and CPSs, which did not reach the required FDA/EMA defined cut-off levels for anti-PD1 or anti-PD-L1 monoclonal antibody treatment for patients with metastatic disease deemed ineligible for cisplatin-based chemotherapy. Here, CD274 is linked to metastatic neoplasm.